EDITOR-IN-CHIEF:

Current Positions and Research Interests
Jan B. Vermorken graduated in 1970 from the University of Amsterdam, the Netherlands and became a board-certified specialist in internal medicine in 1975. Since that time he has worked in the field of Medical Oncology and was officially registered as a Medical Oncologist in the Netherlands in 1992. He received his PhD in Medical Sciences in 1986 from the Vrije Universiteit in Amsterdam. From May 1997 until October 1, 2009, he was Professor of Oncology at the University of Antwerp (UA), and head of the Department of Medical Oncology at the University Hospital Antwerp (UZA), in Edegem, Belgium. After his retirement he remains connected to both University (emeritus Professor) and University Hospital. His main fields of interest are gynecologic oncology, and head and neck oncology. He devotes a significant amount of time to teaching, professional training, and continuing medical education. Professor Vermorken is member of various scientific societies, is member of multiple editorial board of International journals, reviewer of 13 cancer journals and author or co-author of more than 500 publications in international journals. . He has been Editor-in-Chief of Annals of Oncology since January 2009.

Declaration of Interests
Professor Vermorken has acted as a consultant to Merck-Serono, Amgen, Boehringer-Ingelheim, Genmab, Genentech, and Pierre-Fabre. In addition, he has presented data on trabectedin for PharmaMar in a satellite symposium for which he has received an honorarium.

ASSOCIATE EDITORS

Supportive and Palliative Care

Current Positions and Research Interests
Dr. Matti Aapro received his medical degree from the Faculty of Medicine, University of Geneva, Switzerland. He was a fellow at the Arizona Cancer Center in Tucson and was the founding chair of the Medical and Radiation Therapy Department at the European Institute of Oncology in Milano.
He is presently Dean of the Multidisciplinary Oncology Institute, Genolier, Switzerland. Dr. Aapro serves as Executive Director of the International Society for Geriatric Oncology (SIOG). He was member of the Board of the European Organization for Research and Treatment of Cancer (EORTC). Dr. Aapro is a Board Member and past-President of the Multinational Association for Supportive Care in Cancer (MASCC). He chaired the scientific and organizing committees of UICC’s World Cancer Congresses 2008 in Geneva, and 2010 in Shenzhen (China). He is member of the ESMO 2012 Scientific Committee. He coordinates the SPCC programme of the European School of Oncology. Dr. Aapro is Editor-in-Chief of Critical Reviews in Oncology/Hematology, and Associate Editor of Annals of Oncology, Associate Editor for the geriatric section of the Oncologist. He is also member of the editorial board of Journal of Clinical Oncology (breast section) and the Journal of Geriatric Oncology. He has authored more than 250 publications and his major interests are new drug development, breast cancer, cancer in the elderly, and supportive care.

Declaration of Interests
He holds no shares in any drug company or in mutual funds investing exclusively in pharma. He has received study grants, honoraria for consultancy and/or is on the speaker bureau of Abraxis, Amgen, AstraZeneca, Bayer Schering, Bristol-Myers, Celgene, Cephalon, GSK, Helsinn, Hospira, Johnson and Johnson Ortho Biotech, Merck, MSD, Novartis, Pfizer, Pierre-Fabre, Roche, Sandoz, Schering, Sanofi.

Current Positions and Research Interests
Dirk Schrijvers MD, PhD, studied medicine at the Limburgse Universitaire Campus, Diepenbeek, Belgium (1978-1981) and graduated from the Universitaire Instelling Antwerpen, Wilrijk, Belgium (1981-1985). He obtained a degree in Tropical Medicine at the Institute of Tropical Medicine "Prins Leopold", Antwerp, Belgium in 1986. From 1988 till 1993, he went on to specialize in Internal Medicine and Medical Oncology at the Universitaire Instelling Antwerpen, Edegem, Belgium. Dr. Schrijvers obtained his doctoral degree (PhD) in Medical Sciences after defending the thesis: “Anticancer drugs in head and neck cancer: clinical pharmacologic studies." He received postgraduate training in epidemiology and public health, clinical pharmacology, management and palliative care. Working for 2 years in Africa (Franceville, Gabon) at the Centre International de Recherches Médicales he had the opportunity to study infectious diseases. After finishing his specialization in Internal Medicine and Medical Oncology, he was employed at the Department of Medical Oncology of the University Hospital of Antwerp, Edegem, Belgium (1993-2000). Here he was responsible for new drug development, head and neck cancer, and palliative care. From 2000-2001, he worked as a Medical Oncologist at the Department of Medical Oncology of the AZ. Jan Palfijn, Merksem, Belgium.

Actually, he is head of the Department Medical Oncology, Ziekenhuisnetwerk Antwerpen-Middelheim, Antwerp, Belgium and is responsible for new drug development, head and neck cancer, urological cancer and supportive and palliative care.
He published more than 200 articles on infectious diseases, anticancer drugs (phase I, II and III studies), head and neck cancer and palliative care and education in peer-reviewed journals. He both wrote and edited books on oncological emergencies, advanced cancer care, principles of targeted therapy, prostate cancer, palliative care and medical oncology. He is editorial member of journals on cancer treatment, palliative care and studio glass (Fjoezzz). Dr. Schrijvers is a certified member of ESMO (European Society for Medical Oncology) and BSMO (Belgian Society of Medical Oncology). He is Education Chair of the European Cancer Organisation (ECCO) and member of the Palliative Care Working Group and of the Faculty Supportive and Palliative care of the European Society for Medical Oncology (ESMO). He is past chair of the educational committee and of the Publishing Working Group of ESMO. He served as member of the ESMO Board. As a member of the board of “Palliative Hulpverlening Antwerpen (PHA)” and the “Witgele Kruis” dr. Schrijvers actively supports the continuing care of cancer patients outside the hospitals in the Antwerp region. He is also a member of several advisory boards.

Declaration of Interests
Participated in trials sponsored by pharmaceutical companies as Janssen, Johnson & Johnson, Cougar, and Amgen; served on advisory boards of Janssen Pharmaceuticals, Johnson & Johnson, and Sanofi-Aventis, Nycomed; and was invited speaker for Janssen.

Hematologic Malignancies

Current Positions and Research Interests
Dr. James O. Armitage is a graduate of the University of Nebraska Medical Center, completed his internship and residency in internal medicine at Nebraska, a fellowship in hematology oncology at the University of Iowa and a brief stint in private practice in Omaha. He developed and directed the Bone Marrow Transplant program at the University of Iowa and later at the University of Nebraska. He served as Vice-Chair of Internal Medicine, Chair of Internal Medicine, and Dean of the College of Medicine. He currently is The Joe Shapiro Professor of Medicine at the University of Nebraska Medical Center. Dr. Armitage is board certified in internal medicine, medical oncology, and hematology, a Fellow of both the American and Royal College of Physicians, a past member of the National Cancer Advisory Board, past president of the American Society of Clinical Oncology and American Society of Blood and Marrow Transplantation.

Declaration of Interests
Advisor/Consultant, Biogen/IDEC, Advisor, Seattle Genetics, Consultant, Allos, Advisory Board, Ziopharm
Consultant, Eisai, Consultant, Genentech

Current Positions and Research Interests
Dr. Pfreundschuh earned his MD at Heidelberg University in 1975. From 1976 to 1978 he was a clinical fellow at Memorial Hospital and a research fellow at Memorial Sloan Kettering Cancer Center in New York. He completed his training in internal medicine and oncology/haematology at Heidelberg University and Hannover Medical School where he became a faculty member (assistant professor) in 1984. He joined Dr. Diehl from Hannover to Cologne University, where he was appointed as associate professor in 1987. In 1991 Dr. Pfreundschuh was elected as Director of the Department of Internal Medicine and was appointed as Professor for Internal Medicine at Saarland University Medical School. He is a founding member and chairman of the German High Grade Non-Hodgkin-Lymphoma Study Group (DSHNHL). Dr. Pfreundschuh is also a Founding Member of the Academy of Cancer Immunology since 1998. Among other awards, Dr. Pfreundschuh received the William-B.Coley Award for Distinguished Research in Basic and Tumor Immunology in 2000, and the Warner Award for Cancer Research in 2004. Dr. Pfreundschuh´s clinical interests are in oncology, haematology and immunology and his research emphasis is in tumour immunology, cancer immunotherapy, etiology of B-cell malignancies including multiple myelomas, and lymphoma chemo-chemotherapy.

Declaration of Interests
Roche: Advisory Board, honoraria, research support; Amgen: Research support; Pfizer; Sanofi: Advisory Board.

Geriatric Oncology

Current Positions and Research Interests
Lodovico Balducci is Program Leader of the Senior Adult Oncology Program and Medical Director of Affiliates & Referring Physician Relations at H. Lee Moffitt Cancer Center & Research Institute, and Professor of Oncologic Sciences, University of South Florida College of Medicine, in Tampa, Florida. Dr. Balducci received his medical degree from Catholic University, Rome, Italy, and his residency training and fellowship at the University of Mississippi Medical Center, in Jackson, Mississippi. Dr. Balducci has edited five textbooks on geriatric oncology and two books on geriatric hematology. Dr. Balducci has published over 250 articles in various medical journals on the subject of geriatric oncology, and five monographs on geriatric oncology. Dr. Balducci’s clinical research activities include cancer and aging, management of the frail elderly, assessment of quality of life in the older cancer patient, prognostic assessment of the older cancer patient, and interactions of comorbidity and function in the older cancer patient. Dr. Balducci was a member of ASCO’s Grant Selection Committee, and ASCO’s Cancer & Aging Task Force and Oncology Workforce Task Force. He is a member of ASCO Cancer Foundation’s TACF-ASP 2009 Young Investigators Award in Geriatric Oncology Committee. Dr Balducci is a member of the Membership Committee and on the Board of Directors with the Florida Society of Clinical Oncology.

In 2003, Dr. Balducci was selected to present the first Paul Calabresi Memorial Lecture by the International Society of Geriatric Oncology (SIOG) in Rome, Italy. In 2003, he also received the ACCC award for Outstanding Achievement in Clinical Research, and was the 2003 Physician of the Year recipient at the Moffitt Cancer Center. In 2007, he received the Medi Tavossoli Lecture Award for Innovative Research in Hematology in the Elderly and the ASCO’s B.J. Kennedy Award and Lecture for Scientific Excellence. In 2009, he received the 17th Claude Jacquillat Award in Paris and was also the recipient of the 2009 Nimmo Visiting Professorship in Adelaide, Australia. Dr. Balducci is board certified in Medical Oncology/Hematology. He is a member of the American Geriatrics Society, the American Society of Clinical Oncology, American Association for Cancer Research, American Society of Hematology, American Society of Breast Disease, and a fellow of the American College of Physicians. Dr. Balducci has lectured throughout the USA, Europe, Asia, Australia and South America.

Declaration of Interests
Received honoraria from Amgen, Celgene, Novartis and Aventis in the past years.

Current Positions and Research Interests
Hans Wildiers is a medical oncologist dedicated to breast cancer research and geriatric oncology. He is staff member at the department of medical oncology in the University Hospital Gasthuisberg Leuven, Belgium since 2004. He has been coordinator of several academic studies in the field of breast cancer, and author of more than 60 peer reviewed papers. Since July 2003, he is the belgian national representative of SIOG, the international society of geriatric oncology, and is board member of several task forces within SIOG (breast cancer in the elderly, chemotherapy in the elderly, renal function and chemotherapy). He is also board member of the Belgian Society of Medical Oncology (BSMO) since 2007. Since 2008, he is chairmen of the elderly task force cancer of the elderly of the European Organization of Research and Treatment of Cancer (EORTC).

Declaration of Interests
Hans Wildiers has received speakers’ fees from Amgen, GSK, Novartis, Roche, and Sanofi Aventis that were used for scientific purposes, and has received research grants from Amgen, Sanofi-Aventis and Novartis.

Radiation Oncology

Current Positions and Research Interests
After obtaining his degree in Radio-Oncology at the University of Liege, Belgium, Jacques Bernier completed his training at the MD Anderson Cancer Center, Houston, and the Curie Institute, Paris. In 1988 he moved to Switzerland, where he was appointed Chairman of the Radio-Oncology Division, Tessin Cantonal Hospital. In 1995 he received a Privat Docent Chair from the Geneva University. Together with Franco Cavalli, he founded, in the early 2000’s, IOSI – Oncology Institute of Southern Switzerland, in Bellinzona. In 2006 he joined the Swiss Genolier Medical Network, where since then he has been chairing the Radio-Oncology Department.
Throughout most of his career, Jacques Bernier has been heavily involved with translational and clinical research. In 1993 he received the Yalow-Berson Award, in St Louis, USA, for his laboratory work on interferons and interleukins. In a recent past he has been instrumental in introducing the concept of post-operative chemo-radiation in head & neck cancers and leading a seminal EORTC study, the results of which were published in the New England Journal of Medicine.
From 2000 to 2006 Jacques Bernier was Chairman of the Head and Neck Group of the EORTC. He currently serves as an Editorial Board member of various international peer-reviewed journals, including “Journal of Clinical Oncology”.

He is an Associate Editor of “Annals of Oncology” (since 2010), and “Oral Oncology” (since January 2011). In 2010, Jacques Bernier was awarded the “Claudius Regaud Medal” by ESTRO. A Course Director at the European School of Oncology since 1990, Jacques Bernier is also the Chairman of the International Conference on Translational Research in Radio-Oncology - ICTR, organized every three years in Switzerland.

Declaration of Interests
Occasional member of advisory boards, by alphabetical order: AMGEN, Eli-Lilly, GlaxoSmithKline, Merck-Serono, Sanofi-Aventis.

Epidemiology

Dr. La Vecchia received his medical degree from the University of Milan and a master of science degree in clinical epidemiology from Oxford University. He is recognized worldwide as a leading authority in cancer etiology and epidemiology. Presently, he is Chief of Epidemiology at the Mario Negri Institute in Milan, Italy and on the faculty of Medicine at the University of Milan. Dr. La Vecchia serves as an editor for numerous clinical and epidemiologic journals. He is among the most renowned and productive epidemiologists in the field with over 1,560 peer-reviewed papers in the literature and is among the most highly cited medical researchers in the world, according to ISIHighlyCited.comsm, the developer and publisher of the Science Citation Index. Dr. La Vecchia is an Adjunct Professor of Medicine at Vanderbilt Medical Center and the Vanderbilt-Ingram Cancer Center and of Epidemiology at the University of Lausanne, CH. Dr. La Vecchia is a temporary advisor at the International Agency for Research on Cancer IARC/WHO and at the World Health Organization in Geneva, and a registered journalist in Milan. He was Adjunct Associate Professor of Epidemiology at Harvard School of Public Health between 1996 and 2001.

Dr. La Vecchia’s main fields of interest include cancer epidemiology and the risk related to diet, tobacco, oral contraceptive use and occupational or environmental exposure to toxic substances; and analysis of temporal trends and geographical distribution of mortality from cancer, cardiovascular diseases, perinatal and other selected conditions.

Declaration of Interests
No conflicts of interest.

Urogenital Tumors

Current Positions and Research Interests
Karim Fizazi is a medical oncologist, Head of the Department of Cancer Medicine at the Institut Gustave Roussy, Villejuif, France, and full Professor in Oncology at the University of Paris. Pr Fizazi is currently involved in many phase II and phase III clinical trials as a principal investigator. These include GETUG 12 (a 400 patients National phase III trial testing docetaxel–estramustine in high risk localized prostate cancer whose accrual is now completed), GETUG 13 (an ongoing international trial in poor-prognosis non seminomatous germ-cell tumours), and numerous industry-sponsored clinical trials, including the denosumab versus zoledronic acid (103 study), the docetaxel-zibotentan (Enthuse 33), the TAK700 post-docetaxel, and the docetaxel-lenalidomide (Mainsail) large phase III trials in prostate cancer. In 1995 Pr Fizazi attained his medical degree and he completed a Fellowship in 1997 (both in medical oncology). Pr Fizazi gained his PhD in molecular oncology in 2003. He was appointed head of the Department of Medical Oncology at Institut Gustave Roussy in 2005 and full Professor at the University of Paris in 2009.

A member of the European Society of Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR), Pr Fizazi is the President of the French Study Group of Carcinomas of Unknown Primary (GEFCAPI) and is a member of the Urogenital Tumours Study Group (GETUG). Pr Fizazi is associate editor of Annals of Oncology. He has authored numerous posters and abstracts at international congresses and has published over 100 peer-reviewed articles.

Declaration of Interests
Participation to advisory boards and/or speaker for :
Amgen, Astrazeneca, Novartis, Sanofi-Aventis, Keocyt, Ipsen, Janssen/cougar, Astellas/Medivation, BMS, Bayer/Algeta.

Current Positions and Research Interests
Trained in Medicine and Oncology at the University of Sydney, Australia, Dr. Raghavan obtained a PhD in experimental pathology from the University of London/Ludwig Institute for Cancer Research, and then completed post-doctoral studies at the University of Minnesota. After 10 years in Australia, carrying out clinical and laboratory research in genito-urinary and lung cancers, he was recruited to lead Solid Tumor Oncology and Investigational Therapeutics at Roswell Park Cancer Institute, Buffalo, NY, and as Professor of Medicine at SUNY Buffalo. He subsequently was appointed as Associate Director of the USC Norris Comprehensive Cancer Center and Professor of Medicine and Chair of Oncology at the USC School of Medicine, Los Angeles. He took up appointment as Chair & Director of the Cleveland Clinic Taussig Cancer Center in March 2004. Dr. Raghavan has held several peer reviewed research grants in Australia and the USA, has produced about 300 scientific papers, and has edited 9 books. He was also Professor of Medicine at the Lerner College of Medicine of Case Western Reserve University. His clinical and research interests are focused on genitourinary cancer, cancer in the elderly, anticancer drug discovery and development and comparative human oncology. He was elected as a Fellow of the American Association for the Advancement of Science in 2007.

In April 2011, he took up a new appointment as President, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, North Carolina, and also holds a professorial appointment at the University of North Carolina.

Declaration of Interests
International advisory board for Sanofi-Aventis, GU Cancer advisory board for Eli Lilly, Recent research funding (to my institution) for a phase II trial of enzastaurin for prostate cancer (Eli Lilly), One time advisory board for Biogen-Idec >12 months ago - will not be repeated, and may not be even relevant, Intermittent consulting relationship for Gerson Lehrman on strategy of drug development.

Gastrointestinal Tumors

Current Positions and Research Interests
Degree in Medicine and Surgery in 1975; Specialization in Medical Oncology in Jun 1978; Specialisation in Allergology and Clinical Immunology in Jul 1981

PREVIOUS APPOINTMENTS
From 1975- 1980: Research fellow of Medical Oncology Department S. Carlo Borromeo Hospital (Milan); From 1980- 1988: Assistant of Medical Oncology Department S. Carlo Borromeo Hospital (Milan); From 1988- 1997: Deputy Director of Medical Oncology Department S.Carlo Borromeo Hospital (Milan); From 1995- 1997: Responsible of the Group on Gastrointestinal Cancer of Medical Oncology Department S.Carlo Borromeo Hospital (Milan); From November 1997- now: Head of Unit of Medical Oncology – Ospedali Riuniti di Bergamo

MEMBERSHIP TO SCIENTIFIC SOCIETIES
AIOM (Associazione Italiana di Oncologia Medica)as: Regional Councilor (1986/1988); Co-ordinator in Lombardia (1989/1993), National Councillor (1993/1995), National Secretary (1995/now); CIOM (Collegio Italiano degli Oncologi Medici) from 1985; SIC (Società Italiana di Cancerologia) from 1984; ESMO (European Society for Medical Oncology) as: National Representative for Italy (1994/now); ASCO (American Society of Clinical Oncology) from 1994; MASCC (Multinational Association for Supportive Care of Cancer) from 1994; SICP (Società Italiana di Cure Palliative) from 1989; EAPC (European Association of palliative Care) from 1992; SITILO (Società Italiana per le Terapie Integrate Loco

MEMBERSHIP TO SCIENTIFIC GROUPS
GISCAD (Gruppo Italiano per lo studio dei Carcinomi dell’Apparato Digerente)as: Scientific Secretary from 1990; ITMO (Italian Trials in Medical Oncology) as: Member of National Executive Council from 1991; GIVIO (Gruppo Italiano per la valutazione degli interventi in Oncologia) from 1989; EORTC (European Oranization for the Research and Treatment of Cancer) as: Active Member of Gastrointestinal Cooperative Group from 1987; GITCLO (Gastrointestinal Tumour Cooperative Groups Liasison Office) as: National Representative for Italy from 1995
IWGCRC (International Working Group for Colorectal Cancer) from 1995

MEMBERSHIP OF EDITORIAL COMMITTEE
Tumori; Quaderni Cure Palliative; Progress in Colorectal Cancer; Tekve (Update in Oncology and Hematology); Annals of Oncology; Journal of Chemotherapy

Declaration of Interests
No conflicts of interest.

Current Positions and Research Interests
Cornelis (Kees) Jan Alexander Punt, M.D., Ph.D. is a professor in Medical Oncology at the Academic Medical Center at Amsterdam, The Netherlands. He received his MD at the Free University Amsterdam, and was trained as a medical oncologist at the Daniel den Hoed Cancer Centre at Rotterdam. He received is PhD at the University Medical Centre Utrecht in 1991. He was a visiting scientist at the Laboratory of Immunology, Arizona Cancer Center, University of Arizona, Tucson U.S.A. in 1991-1992. He was a professor in Medical Oncology and scientific director of the Institute of Oncology at the Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands until 2011. He is the chairman of the Dutch Colorectal Cancer Group (DCCG), and principal investigator of the DCCG CAIRO studies. His clinical and research interests focus on gastrointestinal cancers.

Declaration of Interests
Advisory role for Merck Serono, Roche

Lung Tumors

Current Positions and Research Interests
Enriqueta Felip is the Head of the Lung Cancer Unit, Oncology Department, Vall d’Hebron University Hospital, Barcelona, Spain. She is Associate Professor of Medicine at the Autonomous University School of Medicine, in the same city.

She is in charge of lung cancer management and is responsible for all lung cancer trials at the Vall d’Hebron University Hospital. Research lines of the Lung Cancer Unit include the optimization of chemotherapy in early-stage disease, evaluation of new drugs and the use of pharmacogenomic approaches.

Enriqueta Felip received her medical degree from the Autonomous University of Barcelona, where she also completed her studies for a PhD in medical oncology. Dr Felip is currently a member of the Spanish Lung Cancer Group, the Spanish Society of Medical Oncology, ESMO, ASCO and IASLC. She is a member of the Scientific Executive Committee of the National Lung Cancer Partnership. She is also the subject editor of Minimum Clinical Recommendations for Diagnosis, Treatment and Follow-up in Lung Cancer for ESMO. Dr Felip has published many peer-review articles and book chapters in this field.

Declaration of Interests
Dr Felip has speakers’ bureau and advisory board roles with Eli Lilly, AstraZeneca, GSK, Merck Serono, Roche, Boehringer Ingelheim.

Current Positions and Research Interests
Dr. Nagahiro Saijo is Professor of Medical Oncology in Kinki University School of Medicine in Osaka. Currently he is the member of officer and the Immediate Past President of the International Association for Study of Lung Cancer, the Past Member of the Board of Directors of the American Society for Clinical Oncology (ASCO), Immediate Past President of the Japanese Society of Medical Oncology (JSMO) and member of National Representative Committee of European Society of Medical Oncology(ESMO). Dr. Saijo received his medical training at the Osaka University School of Medicine. After two years as project investigator in the Department of Developmental Therapeutics at MD Anderson Hospital, he completed his Doctor’s Degree at the Osaka University School of Medicine. During his scientific career, he has been Head of the Department for Internal Medicine at the National Cancer Center Hospital, Chief of the Pharmacology Division of the National Cancer Center Research Institute, Chief of the Medical Oncology Division, Deputy Director of the National Cancer Center Hospital East at the National Cancer Center and Past President of the Japanese Clinical Oncology Group (JCOG).

Dr. Saijo has been awarded the Tamiya Prize, the Award of Adult Disease Memorial Research Foundation, the 5th Central European Lung Cancer Symposium Meritorious Award, a BMS Freedom to Discovery grant,Sagawa Investigator awards and Raymond Bourgine International Awards. He has served as editor, associate editor, editorial board member and reviewer for numerous international and national journals, and has published more than 600 English publications and over 1,000 Japanese publications. His specialties and research interests include Cancer Clinical Trials, Pharmacology and Pharmacogenomics of Anticancer Drugs and Tumor Immunology.

Declaration of Interests
No conflicts of interest.

Head and Neck Tumors

Current Positions and Research Interests
Lisa Licitra is Board-certified in medical oncology, with special expertise in the treatment of head and neck cancers. She is currently assistant physician in charge of the Head and Neck Cancer Medical Oncology Unit at the Istituto Nazionale Tumori in Milan, Italy. Dr. Licitra is Free-contract Professor at State University of Milan, a member of the Clinical Editorial Board of the Journal of Clinical Oncology,Editor of START - State-of-the-Art Oncology in Europe (www.startoncology.net) a project of Alleanza Contro il Cancro – Ministry of Health - Italy, a reviewer of the PDQ Summaries on head and neck cancers, a Board Member of EORTC and European Organization for the Research and Treatment of Cancer and Elected Chair of Head and Neck Cancer Cooperative Group of EORTC, co-founder and member of IGEO - Italian Group for the Evaluation of Outcomes in Oncology, Member of The Educational Committee of ESMO (European Society for Medical Oncology), Chair of the Head and Neck Faculty of ESMO, Co-founder and member, as medical oncologist, for the European Head and Neck Cancer Society, a member of the American Society for Clinical Oncology (ASCO), a member of the Italian Association for Medical Oncology (AIOM) and honorary member of the European Society for Therapeutic Radiology and Oncology (ESTRO). Recently Awarded with the “Guido Venosta” Prize of the Italian Foundation for Cancer Research.

Her main fields of interest are head and neck neoplasms, evidence-based medicine, clinical methodology in oncology, and quality of life. Dr Licitra has written five book chapters and approximately 70 scientific articles.

Declaration of Interests
Consultant/Advisory: BMS, Glaxo, Lilly, Merk-Serono, Amgen
Research funds: EISAI*, Exelixis, Lilly*, Merk-Serono*, Amgen*
Other: Merk-Serono**

* Funds received by my institution for clinical studies and research activities in which I am involved
** Travel coverages for medical meetings

Current Positions and Research Interests
Everett E. Vokes, MD, the John E. Ultmann Professor of Medicine , Chair of Department of Medicine and Physician in Chief at the University of Chicago Medical Center, is an internationally renowned expert in the treatment of head and neck cancer. Dr Vokes served as the Chief of the Section of Hematology/Oncology for 11 years during which time he led the Section to the national prominence it enjoys today as one of the top cancer programs in the country. His has also pioneered the combined use of chemotherapy, radiation and surgery that has resulted in extraordinary advances in the treatment of head and neck cancer, and lung cancer. In early 2009, Dr. Vokes was appointed as Chair of the Department of Medicine a position he held for just seven months before being named as Interim Dean and Chief Executive Officer, Division of the Biological Sciences and the Pritzker School of Medicine on October 1, 2009. On October 1, 2010, Dr. Vokes returned to his role as Chair, Department of Medicine at the University of Chicago and was recently appointed as Physician in Chief for the University of Chicago Medical Center. Dr. Vokes was born in New York City and educated in West Germany, receiving his medical degree from the University of Bonn Medical School.

He served his residency in Internal Medicine at Ravenswood Hospital Medical Center in Chicago and at the University of Southern California in Los Angeles. During this time, Dr. Vokes recognized that systemic therapies could have an effect on cancers. He found it incredibly exciting that oncologists did not always have to use surgery or radiation that intravenous therapies could be given to a patient for treatment to prolong life or result in cure if added to radiotherapy. Out of that realization grew a goal to focus on researching these developments in cancer care. Dr. Vokes arrived at the University of Chicago as a fellow in Hematology/ Oncology in 1983. Upon completion of his fellowship training, he remained on the faculty, and was promoted to Professor in 1995. In 1998, he was named as the John E. Ultmann Professor of Medicine and Radiation and Cellular Oncology. In 2005 he was named as Vice Chair for Clinical Research in the DOM. Dr. Vokes has had a prominent career in clinical and translational research that has helped define commonly used treatment regimens. His work has shown that intense treatment combining radiation and chemotherapy can bring locally advanced head and neck cancer under control and improve survival His research in lung cancer is directed at identifying new active therapeutic agents, as well as the interaction of chemotherapy and radiation therapy.

Dr. Vokes has authored or co-authored more than 450 papers and 80 book chapters. In recognition of his outstanding work, Dr. Vokes has received many awards and has led many professional groups in the field of hematology/oncology. Dr. Vokes is an elected member of the prestigious American Society of Clinical Investigation and American Association of Professors (.He has earned recognition on numerous "best doctor" lists and as one of the first awardees of American Society of Clinical Oncology s Translational Research Professorship. Dr. Vokes has served principal investigator of the University of Chicago's National Cancer Institute Phase II program, supporting numerous phase II studies of novel agents in a network of institutions throughout the Midwest and as the Deputy Director of the University's Comprehensive Cancer Center. He has served on numerous advisory committees and review panels and has served on the editorial boards of several journals, including the Journal of Clinical Oncology, Annals of Oncology, Clinical Lung Cancer, and Investigational New Drugs. The body of Dr. Vokes work not only includes extraordinary research and clinical care but also mentoring the next generation of translational oncologists. His innovative approach to cancer care has been inspiring to young trainees interested in understanding how research can make a difference for patients and lead to positive effect on patient outcomes.

Declaration of Interests
Dr Vokes has acted as a consultant or advisor to Amgen, Poniard, Pfizer, Sanofi-Aventis Imclone, EMD Serono, Genentech, Bristol-Myers Squibb, Veristrat, and GlaxoSmithKline. He has also acted as a review or lecturer for CPRIT, CBCE, SAIC, MD Outlook, IASLC, The Oncologist, Up-to-Date, Research to Practice, AG Communications, Symphony Evolution, Clinical Care Options, One Consortium, Castle Connolly. He serves on the DSMB for Amgen.

Breast Tumors

Current Positions and Research Interests
Monica Castiglione is since June 2011 the director of the Breast Center at the University Hospital in Geneva and since Mai 2010 the Head of the Onco-Gynecologic Unit at the same hospital. Since 2008 she is also consultant in the Breast Center in Zürich. Until the end of 2007 she was staff physician in the Oncology Department of the University Hospital in Bern and CEO of the International Breast Cancer Study Group, an international research group that has dedicated its activity to clinical cancer research in early breast cancer for several decades and has conducted more than 35 large clinical trials in the adjuvant setting of breast cancer. She obtained her PhD at the University of Bern in 1995 and was named Professor of Oncology at the same university in 2000. In 2011 she was named ordinary professor at the Univesity of Geneva. Her main fields of expertise and interest are breast cancer and the conduct of clinical trials, in particular large phase-III trials. She published more than 170 papers in peer-reviewed journals. She is a member of several national and international committees and societies and is member of the editorial boards of several scientific journals.

Declaration of Interests
No conflicts of interest.

Current Positions and Research Interests
Dr Vorobiof has a Medical Doctor degree (1973) from University of Cordoba, Argentina and a Doctor in Medicine degree from the University of Pretoria, South Africa (1987). He is a member of several national and international oncologic societies and served on the International Affairs Committee of the American Society of Clinical Oncology (ASCO) (1999-2001). He is the Regional Representative (Sub-Saharan countries) to the European Society of Medical Oncology (ESMO) (2005-2011) and was a member of the Developing Countries Task Force of ESMO from 2004-2007. He is on the editorial board of various international oncologic medical journals (Annals of Oncology, The Breast, Cancer and Chemotherapy Reviews, the ASCO Post, etc.). Founder member and past Chairman (1999-2005) of the South African Society of Medical Oncology (SASMO). Past Chairman of the South African Melanoma Advisory Board. He has authored and co-authored over 100 peer reviewed articles. He is a member of national and international societies (SASMO, ASCO, ESMO, and ASBD). He has been involved in clinical research with the International Breast Cancer Study Group, the WHO Melanoma Group, EORTC, SAKK, and with other multicentric co-operative clinical trials in South Africa, Europe and North America. His main areas of interest are systemic breast cancer treatments and breast cancer in young adults.

At present and for the past 21 years, he is the Oncology Director of the Sandton Oncology Centre, Johannesburg.

Declaration of Interests
No conflicts of interest.

Gynecologic Malignancies

Current Positions and Research Interests
Jonathan Ledermann is a Professor of Medical Oncology in the UCL Cancer Institute, University College London, and an Honorary Consultant Medical Oncologist at UCL Hospitals. He is Head of the Cancer Research UK & UCL Cancer Trials Centre, within UCL Cancer Institute. He specialises in the treatment of Gynaecological Cancers and works at the North London Gynaecological Cancer Centre, based at the UCL Hospitals. He qualified from the University of London and trained in internal medicine and medical oncology and trained in London and Toronto before joining UCL in 1990. He is the chair of the NCRI Gynaecological Cancer Clinical Studies Group and is a member of the Executive Board of the Gynecologcial Cancer Intergroup. He is a member of the Expert Advisory Group for oncology at the EMA and the Expert Haematology-Oncology Group at the MHRA. His reserearch interests are in clinical trials, experimental therapeutics of ovarian cancer and drug resistance. He has lectured and published widely on these areas of research.

Declaration of Interests
No conflicts of interest

Current Positions and Research Interests
Hiroyuki Yoshikawa, MD, has served as Chair and Professor of Obstetrics and Gynecology (2001- ) and subsequently as Vice-Provost of Comprehensive Human Sciences (2007-2010) at the University of Tsukuba. He studied Medicine at the University of Tokyo and received his M.D. in 1978. Then, he worked at the University of Tokyo Hospital, where he was appointed as Associate Professor of Obstetrics and Gynecology in 1996. In 1986, he received PhD from the Univetrsity of Tokyo, and studied HPV and cervical cancer in Deutsches Krebsforschungszentrum (DKFZ) in Heidelberg, Germany. He has served on the Board of Directors of JSOG (Japan Society of Obstetrics and Gynecology), JSGO (Japan Society of Gynecologic Oncology) and JSMO (Japan Society of Medical Oncology). He was Representative of Gynecologic Cancer Study Group of Japan Clinical Oncology Group (JCOG) (1998-2005), and Representative of Japan Study Group of HPV and Cervical Cancer (1998-). He is Associate Editor of Cancer Science since 2007. Curtently, he is conducting a randomized controlled trial of neoadjuvant chemotherapy for stage III/IV ovarian cancer (JCOG 0602) and a prospective cohort study of CIN 1/2 as the principal investigator.

Declaration of Interests
Hiroyuki Yoshikawa has served on advisory boards for GlaxoSmithKline and MSD since 2006.

Surgical Oncology

Current Positions and Research Interests
Lars Påhlman, born 1946. Completed school 1966 in Sigtuna. Have studied genetics at the University of Stockholm and started 1968 medical school at the University of Uppsala, Sweden. Completed medical school 1973. I had my medical and surgical training at the county hospital of Falun, Sweden. Finished the training period in Falun and moved back to Uppsala 1979 as a consultant surgeon at the University Hospital of Uppsala, Sweden. Finished my thesis about rectal cancer in 1985. Appointed as associate professor of Surgery in 1986 and 1999 professor of surgery at Uppsala University. Since 1989 Head of the Colorectal Unit at the Department of Surgery, University Hospital, Uppsala, Sweden. Have published more than 400 original articles, reviews and book chapter. Has been an invited lecturer numerous times and a visiting professor at 15 different Universities. Have also been president in European Society of Surgical Oncology (ESSO), and European Society of Coloproctology (ESCP). I´m still chairman of European Board of Surgical Qualification, Division of Coloproctology (EBSQ - coloproctology). My main research is to administer large randomised multicentre trials for both benign and malignant colorectal diseases.

Declaration of Interests
No conflicts of interest

Translational Research

Current Positions and Research Interests
Dr Howard McLeod is Fred N. Eshelman Distinguished Professor and Director, UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill. Dr McLeod holds appointments in the Schools of Pharmacy and Medicine, the Carolina Center for Genome Sciences, and the Lineberger Cancer Center. Dr McLeod is chair of the NHGRI eMERGE network external scientific panel and is a member of the FDA committee on Clinical Pharmacology. He also directs the Pharmacogenetics for Every Nation Initiative, which aims to help developing countries use genetic information to improve National Drug Formulary decisions. Howard has published over 380 peer reviewed papers on pharmacogenomics, applied therapeutics, or clinical pharmacology and continues to work to integrate genetics principles into clinical practice to advance individualized medicine.

Declaration of Interests
Medco Health Solutions (member of Laboratory & Therapeutics Advisory Board), Myriad Genetics (consult on Individualized Cancer Therapy), and Gentris Corp (consult on pharmacogenomics in early drug development).

Current Positions and Research Interests
Giampaolo Tortora Is currently Professor of Medical Oncology, and Director of the Medical Oncology Unit at the Medical School and the University Hospital of the University of Verona - Italy. He obtained the M.D. Degree (Summa cum Laude), the Specialty in Oncology (Summa cum Laude), and a Ph.D. in Molecular Biology and Pathology at University of Napoli “Federico II”. He received a research training for almost 5 years at the National Cancer Institute, Bethesda, MD, USA and visited for short stages and lectures several academic and research institutions in Europe and USA. His main research areas are 1) Development of novel targeted agents and therapeutic strategies integrating targeted agents and chemo-radiotherapy; 2) Tyrosine Kinase Receptors, angiogenic factors and microenvironment as targets for cancer therapy; 3) Clinical studies with targeted agents and analysis of biomarkers. Professor Tortora is the author of over 140 publications in international impacted journals, the great majority as senior author, including New England J Medicine, JNCI, PNAS, JCO and Clin Cancer Res, with a total Impact Factor of 860 and H-Index 49. He has received several awards and grants for his studies on novel anticancer targeted agents and is a member of scientific boards and committees of several National and International research societies and organizations, and an Associate Editor/Board member of several scientific journals in th

He teaches Medical Oncology in the residential courses for M.D. students, for residents in Oncology and for Ph.D. students. He lectures in different National and International academic institutions.

Declaration of Interests
No conflicts of interest.

EDITORS EMERITI:

EDITORIAL BOARD:

EXECUTIVE EDITOR

EDITORIAL OFFICE: